Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Long-term antiviral HBV treatment advocated

Study results support the long-term use of tenofovir disoproxil fumarate for chronic hepatitis B virus, showing that it can suppress the virus and lead to regression of fibrosis and cirrhosis in patients after 5 years’ treatment.

17 Dec 2012

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Medivir AB, announced today the initiation of cohort 2 in the interferon-free phase II trial combining simeprevir with sofosbuvir (GS7977) based on a safety and efficacy planned interim analysis of cohort 1 including prior null responder HCV genotype 1 infected patients without advanced hepatic fibrosis.

13 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Patients with sickle cell disease rely more on emergency room

Patients with sickle cell disease rely more on the emergency room as they move from pediatric to adult health care, according to researchers at Washington University School of Medicine in St. Louis.

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

RXi commences RXI-109 Phase 1 study for management of surgical scars and keloids

RXi Pharmaceuticals Corporation, today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated.

5 Dec 2012

Viewpoints: GOP attack on Medicare, Medicaid could hurt critical programs; Will says Obama is repeating his overreach on health care

Congressional Republicans are insisting that big cuts to Medicare and Medicaid be on the table in the negotiations over the so-called fiscal cliff and deficit reduction. That stance is largely a political move against two programs, which have been critical to the public welfare for the past half-century.

30 Nov 2012

First U.S. breathing lung transplant performed in Ronald Reagan UCLA Medical Center

First there was the "heart in a box," a revolutionary experimental technology that allows donor hearts to be delivered to transplant recipients warm and beating rather than frozen in an ice cooler. Now that same technology is being used to deliver "breathing lungs."

27 Nov 2012

CLCA1 molecule plays a special role in the mucus pathway

Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease (COPD) are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions - excess mucus production.

26 Nov 2012

Chronic suppurative lung disease: an interview with Dr Robyn Marsh

Chronic suppurative lung disease, or CSLD, is used to describe a range of lung diseases characterised by a chronic wet cough and progressive lung damage. We are interested in the non-cystic fibrosis forms of the disease with a focus on bronchiectasis – the severe form of CSLD.

26 Nov 2012

First evidence of blood vessel dysfunction found in healthy young people with cystic fibrosis

The first evidence of blood vessel dysfunction has been found in a small cohort of generally healthy young people with cystic fibrosis, researchers report.

26 Nov 2012

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

UNSW-developed nanoparticle could improve effectiveness of chemotherapy for neuroblastoma

In a world-first, researchers from the Australian Centre for Nanomedicine at the University of New South Wales (UNSW) in Sydney have developed a nanoparticle that could improve the effectiveness of chemotherapy for neuroblastoma by a factor of five.

21 Nov 2012

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

21 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

CFFT announces major expansion of research collaboration with Pfizer

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

20 Nov 2012

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood.

17 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

SCCA to raise awareness about importance of lung cancer screening

Lung cancer is the No. 1 cause of cancer deaths in the United States, despite the fact it is largely preventable. For people at high risk of developing lung cancer, such as current or former longtime smokers, screening for the disease with low-dose CT scans is now a viable option that has been shown to significantly reduce mortality rates. In conjunction with National Lung Cancer Awareness Month, Seattle Cancer Care Alliance (SCCA) wants to raise awareness about the importance of prevention and early detection for at-risk populations.

9 Nov 2012

Fibrosis News and Research

Further Reading

Long-term antiviral HBV treatment advocated

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Patients with sickle cell disease rely more on emergency room

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

RXi commences RXI-109 Phase 1 study for management of surgical scars and keloids

Viewpoints: GOP attack on Medicare, Medicaid could hurt critical programs; Will says Obama is repeating his overreach on health care

First U.S. breathing lung transplant performed in Ronald Reagan UCLA Medical Center

CLCA1 molecule plays a special role in the mucus pathway

Chronic suppurative lung disease: an interview with Dr Robyn Marsh

First evidence of blood vessel dysfunction found in healthy young people with cystic fibrosis

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

UNSW-developed nanoparticle could improve effectiveness of chemotherapy for neuroblastoma

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

CFFT announces major expansion of research collaboration with Pfizer

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

SCCA to raise awareness about importance of lung cancer screening

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News